To provide use of dimeric oligocation derivatives for preparing medicaments to prevent or treat inflammatory or neurodegenerative disease, and compounds, pharmaceutical compositions for use of the same.
There are provided low molecular weight apoE mimetic agents suitable for preparing medicaments to treat autoimmune, inflammatory or neurodegenerative disease. The agents are represented by general formula (I): (X)a-L-(X)b, [wherein each X is a (potentially different) chemical moiety bearing a positive charge at physiological pH, a and b are, independently, a number between 3 and 6; and L is a linker]. The compounds may have different X groups (on both sides of the linker L) if each compound has a positive charge at a physiological pH, for example X1-X2-X3-L-X4-X5-X6, X1-X1-X1-L-X2-X3-X4, or X1-X1-X1-L-X2-X2-X2, or X1-X1-X1-L-X2-X2-X2 in the case of each having a positive charge.
FOX DAVID JOHN
古賀 哲次
武居 良太郎
渡辺 陽一
石田 敬
福本 積
青木 篤